

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 5th July 2023.

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **O**- Second line / alternative green drug.
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care.
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
Tranexamic acid nose drops				Requested for Treatment of epistaxis in patients with Hereditary Haemorrhagic Telangiectasia (Osler-Weber-Rendu syndrome). Decision: application withdrawn.
2) New Requests				
Tirbanibulin (Klisyri®▼, Almirall) 10mg/g ointment			✓	Requested for field treatment of non-hyperkeratotic, non hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. Decision: decision deferred to confirm place in therapy compared to other options.
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA881: Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA884: Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA888: Risankizumab for previously treated moderately to severely active Crohn's disease	✓ R			The formulary will reflect the TAG – ICB the responsible commissioner.
TA889: Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA890: Difelikefalin for treating pruritus in people having haemodialysis	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA905: Upadacitinib for previously treated moderately to severely active Crohn's disease	✓ R			The formulary will reflect the TAG – ICB the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Ferric maltol tablets-review of RAG status	✓ ASR			Decision: approve for addition to Harrogate formulary as part of the formulary alignment at current RAG status – Amber SR. Recommend the prescribing information and flow chart on formulary is reviewed and if necessary updated by Gastroenterology and Cardiology and at this point the prescribing advice could be relaunched and would support a review of the current RAG with consideration given to changing to GREEN.
Metolazone to replace xipamide	✓ ASI			Xipamide has now been discontinued. Decision: approved as 2 nd line alternative after bendroflumethazide. Note MHRA Drug Safety Update on differences in bioavailability between licensed metolazone and unlicensed metolazone to prescribers need to be clear on prescription as to what is required.
IQoro® device for stroke-related dysphagia or hiatus hernia	✓ BLACK			Decision: recommended not be prescribed on prescription based on quality of evidence base presented in NICE Medtech briefings for IQoro®.

The following documents/guidelines were presented to and approved at the July 2023 meeting of the APC:

- NY&Y APC biologics Pathway for severe active Crohn's & moderate to severe Ulcerative Colitis - updated

DECISION SUMMARY

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the July 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the July 2023 meeting of the APC:

- Nil this month.

The following documents/guidelines were presented to the July 2023 meeting of the APC for comment:

- Nil this month.